Improved insulin sensitivity and body composition, irrespective of macronutrient intake, after a 12 month intervention in adolescents with pre-diabetes; RESIST a randomised control trial by Ambler, Geoffrey R. et al.
Garnett et al. BMC Pediatrics 2014, 14:289
http://www.biomedcentral.com/1471-2431/14/289RESEARCH ARTICLE Open AccessImproved insulin sensitivity and body composition,
irrespective of macronutrient intake, after a
12 month intervention in adolescents with
pre-diabetes; RESIST a randomised control trial
Sarah P Garnett1,2,3*, Megan Gow1,3, Mandy Ho3, Louise A Baur2,3, Manny Noakes4, Helen J Woodhead5,6,
Carolyn R Broderick7,8, Kerryn Chisholm9, Julie Briody10, Sukanya De2, Katherine Steinbeck11, Shubha Srinivasan1,
Geoffrey R Ambler1,3 and Chris T Cowell1,2,3Abstract
Background: A higher protein to carbohydrate ratio in the diet may potentiate weight loss, improve body composition
and cardiometabolic risk, including glucose homeostasis in adults. The aim of this randomised control trial was to
determine the efficacy of two structured lifestyle interventions, differing in dietary macronutrient content, on insulin
sensitivity and body composition in adolescents. We hypothesised that a moderate-carbohydrate (40-45% of energy),
increased-protein (25-30%) diet would be more effective than a high-carbohydrate diet (55-60%), moderate-protein
(15%) diet in improving outcomes in obese, insulin resistant adolescents.
Methods: Obese 10–17 year olds with either pre-diabetes and/or clinical features of insulin resistance were recruited
at two hospitals in Sydney, Australia. At baseline adolescents were prescribed metformin and randomised to one of
two energy restricted diets. The intervention included regular contact with the dietician and a supervised physical
activity program. Outcomes included insulin sensitivity index measured by an oral glucose tolerance test and body
composition measured by dual-energy x-ray absorptiometry at 12 months.
Results: Of the 111 adolescents recruited, 85 (77%) completed the intervention. BMI expressed as a percentage of the
95th percentile decreased by 6.8% [95% CI: −8.8 to −4.9], ISI increased by 0.2 [95% CI: 0.06 to 0.39] and percent body
fat decreased by 2.4% [95% CI: −3.4 to −1.3]. There were no significant differences in outcomes between diet groups at
any time.
Conclusion: When treated with metformin and an exercise program, a structured, reduced energy diet, which is either
high-carbohydrate or moderate-carbohydrate with increased-protein, can achieve clinically significant improvements in
obese adolescents at risk of type 2 diabetes.
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There is substantial interest in the effect of the macronu-
trient composition of the diet on potentiating weight loss
and improving cardiometabolic risk [1,2]. Results from
several studies indicate that a weight loss diet with in-
creased protein and reduced carbohydrate may increase
body fat mass loss, attenuate loss of fat free mass (FFM)
and improve lipid profile and glucose homeostasis, com-
pared with a conventional high carbohydrate, low fat diet
[3]. It is speculated that protein is superior to carbohy-
drate in promoting satiety as well as dietary induced
thermogenesis, with no unfavourable health implications
[4,5]. In addition, high carbohydrate diets may lead to
higher post prandial glucose and insulin spikes, placing in-
creased demands on beta cell function and exacerbating
insulin sensitivity [6]. However, improved outcomes with
an increased protein diet are not consistently reported. A
recent systematic review [7] identified three randomised
control trials (RCT), conducted in highly controlled en-
vironments, two were in residential camps [8,9] and the
other in a boarding school [10], comparing increased
protein to isoenergetic standard protein diets in obese
children; none reported differences in weight loss, car-
diometabolic risk, or glycaemic status between diets.
However, there is a paucity of trials in free-living over-
weight or obese adolescents.
We undertook an RCT, known as Researching Effective
Strategies to Improve Insulin Sensitivity in Children and
Teenagers (RESIST), with the aim of determining the
effectiveness of a moderate-carbohydrate, increased pro-
tein diet compared to a high carbohydrate diet on insulin
sensitivity in adolescents with pre-diabetes and/or clinical
features of insulin resistance treated with metformin. We
hypothesised that the moderate-carbohydrate, increased-
protein diet would be more effective than the high-
carbohydrate diet in improving insulin sensitivity, body
composition and metabolic profile. The six month results
have been previous published and in contrast to our hy-
pothesis, demonstrated no significant differences in weight
loss or metabolic profile between dietary groups [11]. The
aims of this manuscript are to describe the changes in
whole body insulin sensitivity index (ISI), derived from an
oral glucose tolerance test (OGTT), and in body compo-
sition, measured by dual-energy x-ray absorptiometry
(DXA), after 12 months of intervention.
Methods
This study was a 12 month parallel RCT which took place
at The Children’s Hospital at Westmead (CHW) and
Campbelltown Hospital, Sydney, Australia. This study was
conducted according to the guidelines laid down in the
Declaration of Helsinki and was approved by CHW
Human Research Ethics Committee (07/CHW/12) and
Sydney South West Area Health, Western Zone (08/LPOOL/195). Written informed consent from parents and
assent from the adolescents was sought prior to enrol-
ment. The protocol for the study has been published [12].
All participants were treated with metformin and received
the same 12 month lifestyle intervention. The only dif-
ference between treatment arms was the macronutrient
composition of the diet.
The intervention consisted of three phases:
I (0–3 months): Intensive dietary intervention
II (4–6 months): Intensive exercise program plus
dietary support
III (7–12 months): Participants were encouraged to
continue with their diet/exercise regimens and
metformin.
Study population
Participants were recruited through physician referral
[12]. After a patient was assessed and identified as
meeting the trial criteria, the patient and parent/carer
made contact with study dieticians who explained
the study, sent information sheets/consent forms and
booked appointments. Treatment allocation (allocation
ratio 1:1) occurred centrally by minimisation [13], stra-
tified by sex, pubertal stage and BMI status [14], with
the aid of computer software [15] at CHW, by study
dieticians.
Inclusion criteria
Ten to 17 year old adolescents who were overweight or
obese, as defined by the International Obesity TaskForce
[14] with either pre type 2 diabetes [16] and/or clinical
features of insulin resistance. As previously described clin-
ical features of insulin resistance were defined as a fasting
insulin (pmol/L)/glucose (mmol/L) ratio >20 with one or
more of the following: acanthosis nigricans, polycystic
ovarian syndrome, hypertension, fasting HDL choles-
terol <1.03 mmol/L or fasting triglycerides ≥1.7 mmol/L [12].
Exclusion criteria
Diabetes, contraindications to metformin, secondary
causes of obesity, psychiatric disturbance, significant
mental illness, inability to take part in physical activity,
weight loss medications or medications known to cause
weight gain, and weight >120 kg.
Our target sample size was 108 (54 in each arm). This
was based on the primary outcome, change in whole
body ISI of 0.8 (SD 1.3), with an 80% chance of detecting
a significant increase in ISI at the two sided 5% level and
included a 20% dropout rate [12]. A total of 111 entered
the study between January 2009 and November 2011,
Figure 1.
Excluded (n=31)
Did not meet inclusion 
criteria (n=31)
Declined to participate (n=3)
Allocated (n=111)
Assessed for eligibility (n=145)
Declined to participate (n=43)
Referred (n= 188)
Allocated to a high carbohydrate, 
low fat diet (n=55)
Phase I: Intensive dietary intervention 
Followed up (n=51)
Withdrawals (n=4)
Unrelated medical issues (n=1)
Did not want to participate (n=3)
Allocated to a moderate carbohydrate, 
increased protein diet (n=56)
Phase I: Intensive dietary intervention 
Followed up (n=55)
Withdrawals (n=1) 
Phase II: Intensive exercise intervention   
Followed up (n=49)
Unable to attend 6 month follow-up (n=2)
Withdrawals (n=4) 
Phase II:  Intensive exercise intervention
Followed up (n=49)
Withdrawals (n=2)
Did not want not to participate (n=2)
Phase III:  Maintenance 
Followed up (n=39)
Withdrawals (n=10) 
Not contactable 
Phase III:  Maintenance 
Followed up (n=46)
Withdrawals (n=5)
Did not want not to participate (n=5) 
Figure 1 RESIST participant flow.
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Metformin
Consistent with clinical practice at CHW all participants
were treated with metformin (Diabex) which was pro-
vided at no cost for the duration of the study. The initial
dose was 250 mg twice daily. After 2 weeks this was
increased to a final dose of 500 mg twice daily.
Diet
Diet 1 was a high-carbohydrate diet, with 55-60% of
total energy as carbohydrate (moderate glycaemic load),30% fat (≤10% saturated fat) and 15% protein. Diet 2 was
a moderate-carbohydrate, increased-protein diet, with
40-45% of total energy as carbohydrate (moderate gly-
caemic load), 30% fat (≤10% saturated fat), 25-30% pro-
tein. Diets were prescriptive at two different energy
levels: 6,000 to 7,000 kJ (10 to 14 years) or 7,000 to
8,000 kJ (15 to 17 years). The energy levels were a range
for each age group, to enable prescribed energy to
individualize, depending upon the energy requirements.
Details of the delivery of the intervention have been pre-
viously described [12].
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Phase I Standardised physical activity advice,
consistent with recommendations for
adolescents [17] was delivered by study
dieticians.
Phase II Participants received, free of charge, a
supervised exercise program, 45–60 minutes,
twice/week for 12 weeks in a commercial
gym, including Fitness First, or a local park in
the geographic area in which they lived. The
program was designed to be of moderate-to-
vigorous intensity and consisted of circuit
training with an age-appropriate mix of
resistance and aerobic stations, conducted by
qualified fitness trainers, blinded to treatment
arm. Participants were also encouraged to
exercise at least once a week at home.
Medical care
Clinical progress was reviewed by the participant’s pri-
mary or study physician, who was blinded to the trial
arm of the adolescent and who assessed puberty using
Tanner Staging [18], blood pressure, acanthosis nigricans
[19] and menstrual history.
Outcome measures
All measures were undertaken by clinicians blinded to
treatment allocation at baseline, three and 12 months.
Primary outcome
Insulin sensitivity measured at CHW by whole body ISI
derived from an OGTT using the following formula:
10000=√ð Fasting insulin  fasting glucoseð Þ
 mean 2hr glucose  mean 2hr insulinð ÞÞ
[20].
Secondary outcomes
Change in body composition, anthropometry, acantho-
sis nigricans, triglycerides, HDL-cholesterol and blood
pressure.
Measurements
Weight and height were measured [21] and BMI z-scores
were calculated [22]. BMI was expressed as a percentage
of the 95th centile (BMI%95 centile) [23]. Change in BMI
z-score is not presented, as >96% of the adolescents had
a BMI >97th centile which is beyond the scope of
the CDC2000 reference data [24]. Blood pressure was
measured using an automated blood pressure monitor
(Dinamap 1846SX). Elevated blood pressure was defined
as ≥90th centile [25]. An OGTT was performed after anovernight fast [12]. Blood drawn was analysed using stand-
ard techniques for lipids, alanine aminotransferase (ALT),
gamma-glutamyl transferase (GTT)), and renal function
tests (urea, electrolytes, and creatinine). Abnormal triglyc-
erides and HDL-cholesterol were defined as ≥1.7 mmol/L
and <1.03 mmol/L, respectively. Elevated hepatic transa-
minases were defined as ALT and/or GGT ≥1.5 upper
limit of 30 U/L [26].
Body composition
Body composition was measured by DXA (Prodigy,
Lunar-GE, Madison,WI USA) equipped with propriety
software version13.6. The manufacturer recommended
scan mode, as determined by height and weight, and
when possible, standard positioning techniques were
used. When the adolescent’s width exceeded maximum
scan width, the adolescent was “mummy wrapped”, with
arms placed in a lateral position. Scans were analysed
using manufacturer recommended techniques. Fat mass
index (FMI) and FFM index (FFMI) were calculated as
fat mass (g)/height (cm)2 and FFM (g)/height (cm)2, re-
spectively [27].
Dietary intake
Dietary intake was obtained by 24-hour dietary recalls at
6 weeks and 3, 6 and 12 months. This procedure was
conducted by dieticians using a standardised three-pass
methodology and food model booklet as previously de-
scribed [12]. Energy and macronutrient intake were esti-
mated using Foodworks 2009 (version 6.0.2539; Xyris
Inc., Brisbane, QLD, Australia).
Metformin compliance
Adherence was assessed by pill counts by the clinical
trials pharmacist at CHW. After three months of inter-
vention, 69 (62%) participants returned pills and after
6 months 50 (45%) participants returned pills. There was
no difference between diet groups in adherence at either
time period. At three months it was estimated the par-
ticipants took (median [interquartile range]) 88% [61 to
98] of prescribed metformin and after 6 months parti-
cipants took 65% [38 to 94]. There was no pill count at
12 months. As previously reported 16 (14%) participants
reported side effects to metformin [11].
Statistical analysis
Data were analysed using PASW statistical software for
Windows, version 18 (SPSS Inc). Differences between
continuous data were examined using independent sample
t-tests for normally distributed data or Mann–Whitney
tests for non-parametric data. Chi-squared tests were used
to examine differences in categorical data; odds ratios
were used to examine the magnitude of the association.
Correlations between variables were assessed by Pearson’s
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distributed and non-parametric data, respectively. Consist-
ent with an intent-to-treat approach, all available data for
participants as originally randomly assigned, were retained.
Linear mixed models with an unstructured covariance
were used to test for the effects of diet and time (baseline,
three, six and 12 months). Non-parametric data were log
transformed. Age at baseline and age difference between
visits were tested in the modelling but were not statistically
and/or clinically significant and hence results have been
expressed as unadjusted models. The least significant dif-
ference method was used for post-hoc comparisons. The
assumptions of modelling were tested and met. Mean
changes and differences derived from linear mixed models
are presented with 95% CIs. Data that were log trans-
formed are presented as geometric means with 95% CIs.
Results
Of the 111 adolescents (66 girls) recruited, 85 (77%)
completed the 12 month intervention (Figure 1). ThereTable 1 Baseline characteristics
Intervention group
Moderate-carbohydrate, increased-p
Age and sex
Age years median [range] 13.0 [10.1 to 16.5]
Girls n (%) 34 (60.7)
Pubertal status‡ n (%)
Tanner stage 1 7 (12.7)
2 9 (16.4)
3 15 (27.3)
4 15 (27.3)
5 9 (16.4)
Anthropometry
Mean (SD) unless otherwise indicated
Weight kg 90.7 (19.0)
Height z-score 1.27 (1.29)
Weight z-score 2.73 (0.53)
BMI z-score 2.39 (0.25)
BMI %95 centile 133 (19)
Obese§ n (%) 55 (98.2)
Body composition (DXA)|
Total body fat (kg) 43.5 (10.0)
Total fat % 49.5 (5.5)
Total fat free mass (kg) 44.4 (11.3)
Fat free mass index 1.66 (0.24)
*P independent sample t-tests unless otherwise indicated.
†Chi-squared test.
‡One girl in the moderate carbohydrate, increase protein diet group had missing da
§Obesity defined by International Obesity Taskforce [14].
|DXA: Dual-energy x-ray absorptiometry.was no statistical difference in baseline anthropo-
metry, body composition or clinical parameters between
groups (Table 1). The exception was that more partici-
pants had pre-diabetes in the moderate-carbohydrate,
increased-protein group (n = 11; 19.6%) compared to
the high-carbohydrate group (n = 3; 5.5%), P = 0.024.
There was also no statistical difference in baseline
anthropometry, body composition or clinical parame-
ters between the completers and the drop-outs. Partici-
pants who dropped out were more likely to come from
a single parent family (odds ratio 4.3 [95% CI: 1.6 to
12.0], P = 0.05). Attrition rate was not statistically sig-
nificantly different between diet groups (Figure 1). Over
the 12 month intervention there was a statistically sig-
nificant (P < 0.001) decrease in height z-score from 1.27
at baseline to 0.76 at 12 months and the number of
children who were pre-pubertal (Tanner stage 1 and 2)
decreased from 30.9% to 15.1%. The change in height
and pubertal stage was not significantly different bet-
ween diet groups.rotein diet (n = 56) High-carbohydrate, low-fat diet (n = 55) P*
13.2 [10.2 to 17.4] 0.959
32 (58.2) 0.786†
7 (12.7)
11 (20.0)
9 (16.4)
16 (29.1)
12 (21.8)
90.7 (21.2) 0.992
1.30 (1.11) 0.894
2.68 (0.57) 0.646
2.33 (0.32) 0.253
132 (23) 0.770
52 (94.5) 0.300†
42.6 (11.7) 0.683
48.3 (5.7) 0.249
45.1 (11.4) 0.740
1.69 (0.29) 0.638
ta.
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ISI increased between baseline and three months, which
remained significantly different from baseline at 12 months;
estimated mean difference 0.23 [0.06 to 0.39], P = 0.009;
Figure 2a. The magnitude of change was similar for girls
and boys, although boys commenced the trial with a
lower median ISI (1.2 [range 0.3 to 3.0]) compared to
girls (1.4 [0.3 to 3.4]), P = 0.04. Adjusting for puberty
and/or age did not alter the outcome. There was no sig-
nificant difference in ISI between diet groups at any
time point.
Effects of intervention on total body fat
Total body fat% decreased over the 12 month interven-
tion (P < 0.001, Figure 2b). There was a significant sex
and pubertal interaction in the modelling. After adjus-
ting for pubertal stage, the magnitude of change was
similar for boys and girls, however, boys commenced theFigure 2 Glycemic status and body composition measures by dietary
(SE) are presented from linear mixed models for the moderate-carbohydrat
group (△). a: Insulin sensitivity index. 1Significance between baseline and 3
12 months. b: Total body fat percent measured by dual energy x-ray absor
and 12 months as indicated. 2Significance between 3 and 12 months. c: Fa
12 months as indicated. 2Significance between 3 and 12 months. d: BMI%9
and 12 months as indicated. 3Significance between 3 and 6 months. 4Signitrial with a lower total body fat percentage (46.3% ± 5.3)
compared to girls (50.7% ±5 .3), P < 0.001. There was no
significant difference in total body fat% between diet
groups at any time point. Similarly the FMI significantly
(P = 0.009) decreased from 16.2 ± 0.4 (estimated mar-
ginal mean ± SE) at baseline to 15.6 ± 0.5 at 12 months
and there was no significant difference (P = 0.421) in
FMI between diet groups at any time point.
Effects of intervention on fat free mass index
After three months of intervention there was a signifi-
cant decrease in FFMI, followed by a significant increase
between three and 12 months (Figure 2c). Analysis stra-
tified by sex indicated that girls, but not boys, had a sig-
nificant decrease; estimated mean difference (0.03 [95%
CI: 0.01 to 0.05], P = 0.005) in the FFMI during the first
three months, which increased (0.03 [0.001 to 0.06],
P = 0.014) to baseline levels at 12 month. Boys’ FFMI didgroup over the 12 month intervention. Estimated marginal means
e, increased-protein diet group (▼) and the high-carbohydrate diet
months and 12 months as indicated. 2Significance between 3 and
ptiometry (Fat % DXA). 1Significance between baseline and 3 months
t free mass index. 1Significance between baseline and 3 months and
5th centile. 1Significance between baseline and 3 months, 6 months
ficance between 6 and 12 months.
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higher at 12 months compared to both baseline (0.09
[0.06 to 0.12], P < 0.001]) and three months (0.11 [0.06
to 0.15], P < 0.001). Adjusting for puberty and/or age did
not alter the outcome. There was no significant diffe-
rence between diet groups at any time point.
Effects of intervention on BMI%95th centile
BMI%95th centile decreased between baseline and
12 months (P < 0.001, Figure 2d). The decrease in BMI%
95th centile occurred between baseline and six months
and there was no significant change over the following
six months. The magnitude of change (estimated mean
difference 6.8% [95% CI: 4.9 to 8.8]) over the 12 months
was similar for boys and girls, although boys com-
menced the trial with a higher mean (±SD) BMI%95th
centile compared to girls; 136.8 ± 21.1 and 129.3 ± 20.6,
P = 0.020, respectively. There was no significant diffe-
rence between diet groups at any time point.
Effects of intervention on lipids and blood pressure
Between baseline and 12 months there was a significant
increase in HDL-cholesterol and a significant decrease
in diastolic blood pressure (Table 2). There were no sig-
nificant differences between baseline and 12 month mea-
sures of LDL-cholesterol , triglycerides or systolic blood
pressure, nor was there any significant difference in
lipids or blood pressure between diet groups at any time
point. Sex was not a significant predictor of change in
HDL-cholesterol, LDL-cholesterol or triglycerides. How-
ever, a sex difference in blood pressure was observed.
The magnitude of change in both SBP z-score and DBP
z-score over the 12 months was similar for boys and
girls, although boys commenced the trial with a higher
blood pressure. At baseline the SBP z-score (estimated
marginal mean (SE)) for boys and girls was 1.10 (0.14)
and 0.49 (0.16), respectively and DBP was 1.13 (0.09)
and 0.75 (0.11), respectively.
Dietary adherence
The geometric mean [95% CI] for the reported energy
intake over the 12 month intervention was 5.97 [5.94 to
6.37] MJ per day for adolescents randomised to theTable 2 Lipids and blood pressure at baseline and 12 months
Baseline
Triglycerides mmol/L† 1.1 [1.0-1.2]
HDL-C mmol/L 1.05 (0.02)
LDL-C mol/L 2.77 (0.08)
SBP z-score 0.79 (0.12)
DBP z-score 0.94 (0.08)
*Pairwise comparison with baseline.
†Geometric mean [95% CI].
Estimated marginal means (SE) are presented from linear mixed models, unless othmoderate-carbohydrate, increased-protein diet and 6.41
[6.00 to 6.85] MJ per day for adolescents randomised to
the high-carbohydrate diet. The difference was not signifi-
cant (P = 0.126), nor did the reported energy intake differ
over time (P = 0.935). Protein % energy was significantly
(P = 0.027) higher in the moderate-carbohydrate increased-
protein group compared to the high-carbohydrate group,
20.3% [19.3 to 21.2] and 18.8% [17.8 to 19.2], respectively,
and this did not differ over time (P = 0.081). There was no
statistical difference in reported fat % energy (both groups
30.4% [28.5 to 32.2], P = 0.710) or carbohydrate % energy
(46.5% [44.7 to 48.1] for the increased-protein group and
48.2% [46.4 to 49.9] for the high-carbohydrate group,
P = 0.155). Fat % energy intake did not change significantly
over time (P = 0.191). In contrast, reported carbohydrate
% energy was significantly higher in both groups at
six months compared to six weeks, three months and
12 months, P = 0.003.
Clinical outcomes in adolescents who completed the
intervention
There was no statistical difference in clinical outcomes
between diet groups at any time point; data has been
pooled for this analysis, Table 3.
BMI %95th centile
Of the 85(82 obese at baseline) who completed the study,
67 (78.8%) decreased BMI %95th centile and 18 increased
BMI %95th centile. Two participants completed the
12 month intervention with a weight within the normal
range, and 12 were classified as overweight. Baseline sex,
age, puberty, weight, or fasting insulin were not signifi-
cantly associated with change in BMI %95th centile. How-
ever, participants who entered the trial with a higher ISI,
lost less weight (BMI %95th centile), rho −0.26, P = 0.018.
Pre-diabetes
Eighty-three participants had glycaemic status measured
at baseline and 12 months. Eight (9.6%) of the 83 partici-
pants had pre-diabetes at baseline (three impaired fasting
glucose (IFG), four impaired glucose tolerance (IGT), one
with both IFG and IGT), but only 2 had pre-diabetes at
12 months. The six participants who improved glycaemicAfter 12 months intervention P*
1.0 [0.9-1.1] 0.209
1.12 (0.03) <0.001
2.75 (0.08) 0.456
0.65 (0.12) 0.270
0.74 (0.10) 0.047
erwise indicated.
Table 3 Clinical presentation at baseline, 3, 6 and 12 months
Baseline 3 months 6 months 12 months
n = 111 n = 106 n = 100 n = 85
Acanthosis nigricans present 94 (84.7) 88 (83.8)* 79 (85.9)† 61 (76.3)§
Pre-diabetes 14 (12.6) 19 (17.9) 10 (12.1)†,**
Dyslipidaemia 61 (55.0)* 57 (54.3)* 51 (53.7)| 32 (28.8)†
(HDL-C <1.03 mmol/L and/or triglycerides ≥1.7 mmol/L)
SBP and/or DBP ≥90 percentile 49 (44.1) 41 (38.7) 30 (30.6)† 37 (43.5)
Elevated liver enzymes (ALT and/or GGT ≥1.5 upper limit of 30 U/L) 22 (20.0)† 21 (20.4)‡ 17 (17.3)† 14 (12.6)‡
Microalbuminuria 9 (8.5)§ 9 (8.9)§ 9 (9.5)§ 9§ (8.1)§
(Urine/albumin/creatinine, Girls: 3.5 to 25 mg/mmol, Boys: 2.5 to 25 mg/mmol)
*1 missing value, †2 missing values, ‡3 missing values, §5 missing values, | 8 missing values **including one adolescent diagnosed with type 2 diabetes.
Values are n (%).
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95th centile decreased by −21.3 [95% CI:-34.3 to −8.2]),
total fat % decreased by −8.7 [−22.3 to 1.7] and ISI in-
creased by 1.0 [0.02 to 3.6]. An additional 8 participants
developed pre-diabetes over the 12 months and one, an
11 year old boy, gained 16 kg and developed type 2
diabetes.
Acanthosis nigricans
Eighty participants were assessed for acanthosis nigricans
at baseline and 12 months, of which 66 (82.5%) entered
the trial with acanthosis nigricans. After the 12 month
intervention acanthosis nigricans resolved in seven partici-
pants and developed in two. Those who had resolution
lost more total body fat % compared to those who did not,
mean difference in total body fat % 4.7 [95% CI:1.6 to 7.8],
but there was no significant difference in ISI.
Dyslipidemia
Eighty-two participants had blood lipids measured at
baseline and 12 months, of which 46 (56.1%) entered the
trial with dyslipidaemia. After 12 months of intervention,
dyslipidaemia resolved in 19 (23.2%) participants and de-
veloped in 5 (6.1%). There were no statistical differences
in change in BMI %95th centile, total body fat% or ISI
between those who did or did not have resolution.
Blood pressure
All participants who completed the interventions had
blood pressure measured at baseline and 12 months, of
which 49 (44.1%) entered the trial with elevated blood
pressure. After 12 months of intervention, blood pres-
sure decreased to normal levels in 12 (14.1%) par-
ticipants and increased in 12 (14.1%). There was no
statistical difference in the number of participants with
elevated blood pressure at any time point (P = 0.183).
There were no statistical differences in change in BMI %
95th centile, total body fat% or ISI between those who
did or did not have improved blood pressure.Discussion
Overall, results from this study indicate that a 12 month
lifestyle intervention combined with metformin therapy
in overweight and obese adolescents at risk of deve-
loping type 2 diabetes was effective in achieving mo-
derate improvement in body composition and BMI.
Pre-diabetes and clinical features including acanthosis
nigricans, also improved, particularly in adolescents who
lost weight (BMI % 95th centile) and/or total body fat %.
ISI also increased significantly; however, the magnitude
of difference between baseline and 12 months was small
and may not be clinically significant. In contrast to our
hypothesis, that adolescents randomised to a moderate-
carbohydrate, increased-protein diet would have better
outcomes compared to the high-carbohydrate diet, the
diets had no differential effect on any outcome measure,
at any time point. These results are consistent with three
other RCTs in overweight and obese adolescents that in-
vestigated the effect of varying protein content com-
pared with control diets on weight loss in residential
settings [7] but in contrast to those from a recent sys-
tematic review of RCTs in overweight and obese adults
[3]. To our knowledge, there is only one study, the Di-
ogenes study, which has shown a beneficial effect of in-
creasing the protein in the diet, particularly when
coupled with a low glycaemic diet, on both body fat and
cardiometabolic markers in children [28,29]. There are a
number of reasons why the results may differ from our
study and others, including study design; in the Diogenes
study families were randomised, not children and the
focus was children at risk of obesity and weight mainten-
ance, not obese children and weight loss.
The lack of effect between diets in our study may be
due to poor compliance. Many participants had difficulty
in achieving the macronutrient goals of the prescribed
diet and the mean difference in protein intake was mar-
ginal (<2% of energy). However, the results remained un-
changed in post-hoc analysis of those who were able to
meet the targets. Our study was undertaken in a real-life
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consequence of inadequate protein targets or a con-
sequence of readily available high carbohydrate snack
foods.
The specific effect of metformin therapy on outcome
measures in our study is not clear. The beneficial effects
of metformin therapy combined with lifestyle interven-
tions in adolescents with clinical features of insulin re-
sistance are well documented [30,31]. However, results
from the largest randomised, placebo controlled trial of
metformin alone, on weight and metabolic markers in
150 obese adolescents with hyperinsulinemia and/or
pre-diabetes, indicated no significant change in ISI after
three and six months of metformin therapy [32]. There
are no RCTs which have compared lifestyle interventions
to metformin therapy alone in adolescents. We speculate
that it is the combined effect of metformin therapy and
lifestyle intervention which resulted in weight loss and
improved glycaemic status in our study. It should also
be noted that the improvement in ISI occurred during
puberty, a time when insulin sensitivity is expected to
decrease irrespective of body composition [33].
The magnitude of total fat % loss after the 12 month
intervention was small (−2.4%), although similar to other
studies examining the impact of dietary and exercise in-
terventions in obese adolescents and children [30]. How-
ever, we may have expected many of the participants to
be increasing body fat as part of normal growth and de-
velopment during puberty [24]; the number of children
who were pre-pubertal (Tanner stage 1 and 2) decreased
from 30.9% to 15.1% over the 12 months. Loss of total
fat% was not associated with resolution of dyslipidemia
or lowering of blood pressure; previous studies have re-
ported mixed results [34].
Limitations of the study including the use of ISI to
measure glycaemic status, proxy measures of dietary com-
pliance (24 hour recalls) and non-blinding of participants
and dieticians. Lack of baseline dietary intake meant that
we were unable to determine whether intake was altered
by either dietary intervention. However, both groups lost
similar amounts of weight, indicating that the energy def-
icit is likely to be similar in both diet groups. Another
limitation was that metformin adherence was not mea-
sured at 12 months, hampering our interpretation of the
effect of lifestyle compared to metformin therapy.
A strength of the study was the retention rate. After
the six month intensive lifestyle intervention, including
regular dietary counselling, food hampers to support the
prescribed diet, a three month supervised physical activ-
ity program and email support, we retained 88% of those
recruited. After 12 months, the last six months being a
maintenance phase with regular, but limited contact with
health professionals, we retained 77%. The challenges
of recruitment and retention of adolescents have beenpreviously described [35]. Most (77%) adolescents that
dropped out reported lack of interest, highlighting that
one program does not suit everyone and alternative ap-
proaches to managing adolescents with insulin resistance/
pre-diabetes are required. Food preferences are personal;
dietary modification may need to be individualised.
Conclusion
Reduced energy intake, combined with physical activity
and assisted by metformin, is likely to be the mainstay
for improving insulin sensitivity in this large RCT, com-
pleted in a challenging developmental stage. We were
unable to demonstrate that the two study diets had
differential effects on ISI, body composition or BMI, at
any time point. This finding and the improvement in
acanthosis nigricans, as a clinical indicator of insulin re-
sistance suggest that a prescribed reduced energy diet is
the important intervention message rather than diet
composition for overweight and obese adolescents at
risk of type 2 diabetes.
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